Filing Analysis
Officer Departure
Filed Mar 27, 2026
LOW
MaxCyte, Inc. has appointed Parmeet Ahuja as its new Chief Financial Officer and principal accounting officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky as part of a planned leadership transition first announced in November 2025.
Key Facts
- Parmeet Ahuja appointed CFO effective March 30, 2026, succeeding Douglas Swirsky.
- Mr. Ahuja previously served as Vice President of Investor Relations and Vice President of FP&A at Agilent Technologies, Inc.
- Compensation includes an annual base salary of $450,000 and a target performance bonus of 50%.
- Inducement equity grants consist of 375,000 stock options and 187,500 restricted stock units (RSUs).
- Severance terms include 12 months of salary and bonus in a change-of-control scenario, or 9 months of salary for other qualifying terminations.
Regulation FD Disclosure
Filed Mar 24, 2026
LOW
MaxCyte, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided an updated corporate presentation for investors.
Key Facts
- Announced financial results for the fiscal year ended December 31, 2025, on March 24, 2026.
- Updated corporate presentation posted to the company's investor relations website.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- Information in the report is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Delisting Notice
Filed Mar 20, 2026
HIGH
MaxCyte, Inc. received a deficiency notice from Nasdaq on March 16, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive trading days. The company has until September 14, 2026, to regain compliance by maintaining a $1.00 bid price for at least 10 consecutive business days.
Red Flags
- Non-compliance with Nasdaq minimum bid price requirements.
- Potential for a reverse stock split if the share price does not recover organically.
- Risk of delisting if the company cannot meet requirements or qualify for an extension.
Key Facts
- Notice received from Nasdaq on March 16, 2026, regarding non-compliance with Listing Rule 5450(a)(1).
- The stock price closed below $1.00 for 30 consecutive trading days.
- The company has an initial 180-day grace period ending September 14, 2026.
- To cure the deficiency, the stock must close at or above $1.00 for at least 10 consecutive trading days.
- If compliance is not met by the deadline, the company may apply for an additional 180-day period by transferring to the Nasdaq Capital Market.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.